美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Sucampo Pharmaceuticals

18.00

0.0000

成交量：- -

成交額：- -

市值：8.39億

市盈率：-5.47

高：18.00

開：18.00

低：18.00

收：18.00

52周最高：18.75

52周最低：9.30

股本：4,663.70萬

流通股本：2,434.00萬

量比：- -

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-3.2900

淨資產收益率：--

總資產收益率：--

市淨率：21.18

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

公司資料

公司名字：

Sucampo Pharmaceuticals

交易所：

NASDAQ

成立時間：

- -

員工人數：

- -

公司地址：

- -

官網：

http://www.sucampo.com

郵編：

- -

電話：

- -

傳真：

- -

簡介：

Sucampo Pharmaceuticals, Inc.是根據美國特拉華州法律註冊成立於1996年12月。該公司是一家國際製藥公司專註於基於前列酮的專利藥物的發現，開發和商業化。前列酮是一類脂肪酸化合物，在人體內自然產生的由類花生酸類物質的15-羥基前列腺素脫氫酶（15-PGDH）的酶催化的結果，如前列腺素和其他類二十二烷酸分子與15位酮基特異性合成。在兩種性別的成年人，AMITIZA（魯比前列酮）被批准用於循環免疫複合物的處理，而對於便秘的治療，適應人群是女性年齡在18歲以上。該公司目前正在開發AMITIZA來治療阿片樣物質引起的便秘或阿片樣物質引起的腸胃功能障礙。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣0平台費、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SCMP/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SCMP","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCMP\",,,,,undefined,":{"symbol":"SCMP","market":"US","secType":"STK","nameCN":"Sucampo Pharmaceuticals","latestPrice":18,"timestamp":1557518400000,"preClose":18,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":24340000,"shares":46637000,"eps":-3.29,"marketStatus":"退市","change":0,"latestTime":"05-10 16:00:00 EDT","open":18,"high":18,"low":18,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.29,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1186027200000,"exchange":"NASDAQ","adjPreClose":18,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SCMP\",,,,,undefined,":{"symbol":"SCMP","floatShares":24340000,"roa":"--","roe":"--","lyrEps":0,"shares":46637000,"dividePrice":0,"high":18,"amplitude":0,"preClose":18,"low":18,"week52Low":9.3,"pbRate":"21.18","week52High":18.75,"institutionHeld":0,"latestPrice":18,"eps":-3.29,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.29,"open":18},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SCMP\",params:#limit:5,,,undefined,":[{"market":"US","date":"2017-11-01","symbol":"SCMP","fiscalQuarterEnding":"2017/09","expectedEps":0.25,"name":null,"time":"盤前","type":"earning","dateTimestamp":1509508800000,"reportTimeType":"pre","actualEps":0.27},{"market":"US","date":"2017-08-02","symbol":"SCMP","fiscalQuarterEnding":"2017/06","expectedEps":0.22,"name":null,"time":"盤前","type":"earning","dateTimestamp":1501646400000,"reportTimeType":"pre","actualEps":0.28},{"market":"US","date":"2017-05-03","symbol":"SCMP","fiscalQuarterEnding":"2017/03","expectedEps":0.26,"name":null,"time":"盤前","type":"earning","dateTimestamp":1493784000000,"reportTimeType":"pre","actualEps":0.23},{"market":"US","date":"2017-03-08","symbol":"SCMP","fiscalQuarterEnding":"2016/12","expectedEps":0.49,"name":null,"time":"盤前","type":"earning","dateTimestamp":1488949200000,"reportTimeType":"pre","actualEps":0.68},{"market":"US","date":"2016-11-09","symbol":"SCMP","fiscalQuarterEnding":"2016/09","expectedEps":0.26,"name":null,"time":"盤前","type":"earning","dateTimestamp":1478667600000,"reportTimeType":"pre","actualEps":0.28}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SCMP\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SCMP\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.sucampo.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Sucampo Pharmaceuticals, Inc.是根據美國特拉華州法律註冊成立於1996年12月。該公司是一家國際製藥公司專註於基於前列酮的專利藥物的發現，開發和商業化。前列酮是一類脂肪酸化合物，在人體內自然產生的由類花生酸類物質的15-羥基前列腺素脫氫酶（15-PGDH）的酶催化的結果，如前列腺素和其他類二十二烷酸分子與15位酮基特異性合成。在兩種性別的成年人，AMITIZA（魯比前列酮）被批准用於循環免疫複合物的處理，而對於便秘的治療，適應人群是女性年齡在18歲以上。該公司目前正在開發AMITIZA來治療阿片樣物質引起的便秘或阿片樣物質引起的腸胃功能障礙。","exchange":"NASDAQ","name":"Sucampo Pharmaceuticals","nameEN":"Sucampo Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"SCMP\",market:\"US\",,,undefined,":null}}